MDGA1

Summary

MDGA1 (MAM domain containing glycosylphosphatidylinositol anchor 1, HGNC:19267) is a protein-coding gene on chromosome 6p21.2, encoding MAM domain-containing glycosylphosphatidylinositol anchor protein 1 (Q8NFP4). Required for radial migration of cortical neurons in the superficial layer of the neocortex.

This gene encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is expressed predominantly in the developing nervous system. In addition to possessing several cell adhesion molecule-like domains, the mature protein has six Ig-like domains, a single fibronectin type III domain, a MAM domain and a C-terminal GPI-anchoring site. Studies in other mammals suggest this protein plays a role in cell adhesion, migration, and axon guidance and, in the developing brain, neuronal migration. In humans, this gene is associated with bipolar disorder and schizophrenia.

Source: NCBI Gene 266727 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 148 total
• MANE Select transcript: NM_153487

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19267
Approved symbol	MDGA1
Name	MAM domain containing glycosylphosphatidylinositol anchor 1
Location	6p21.2
Locus type	gene with protein product
Status	Approved
Aliases	GPIM, MAMDC3
Ensembl gene	ENSG00000112139
Ensembl biotype	protein_coding
OMIM	609626
Entrez	266727

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 8 protein_coding, 3 nonsense_mediated_decay, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000373401, ENST00000418178, ENST00000434837, ENST00000478143, ENST00000502298, ENST00000505425, ENST00000508399, ENST00000510077, ENST00000515437, ENST00000650466, ENST00000680397, ENST00000681439, ENST00000681472, ENST00000955606

RefSeq mRNA: 1 — MANE Select: NM_153487 NM_153487

CCDS: CCDS47417

Canonical transcript exons

ENST00000434837 — 17 exons

Exon	Start	End
ENSE00000750150	37638537	37638667
ENSE00001027646	37647173	37647324
ENSE00001085862	37648982	37649266
ENSE00001085864	37654800	37654932
ENSE00001192353	37646198	37646375
ENSE00001271144	37696745	37697883
ENSE00001271157	37650109	37650405
ENSE00001271167	37655700	37655896
ENSE00001460477	37645933	37645956
ENSE00002067969	37630679	37637459
ENSE00003490505	37663967	37664106
ENSE00003538223	37643809	37643943
ENSE00003544477	37654274	37654543
ENSE00003577669	37658245	37658419
ENSE00003631148	37644497	37644649
ENSE00003656202	37652011	37652340
ENSE00003677673	37638205	37638313

Expression profiles

Bgee: expression breadth ubiquitous, 223 present calls, max score 98.18.

FANTOM5 (CAGE): breadth broad, TPM avg 2.1757 / max 280.1258, expressed in 673 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73448	1.1811	323
73445	0.3057	117
73446	0.1921	73
73449	0.1894	77
73450	0.1166	39
73440	0.0606	10
73447	0.0444	14
73438	0.0410	13
73444	0.0216	9
73442	0.0107	3

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar hemisphere	UBERON:0002245	98.18	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.18	silver quality
cerebellar cortex	UBERON:0002129	98.08	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.73	gold quality
left ventricle myocardium	UBERON:0006566	97.40	silver quality
cerebellum	UBERON:0002037	97.11	gold quality
kidney epithelium	UBERON:0004819	95.45	silver quality
nasal cavity epithelium	UBERON:0005384	92.89	silver quality
upper arm skin	UBERON:0004263	92.55	silver quality
lower esophagus mucosa	UBERON:0035834	90.09	gold quality
myocardium	UBERON:0002349	89.28	silver quality
lateral globus pallidus	UBERON:0002476	88.60	gold quality
vena cava	UBERON:0004087	88.57	gold quality
epithelial cell of pancreas	CL:0000083	88.42	silver quality
lateral nuclear group of thalamus	UBERON:0002736	86.43	silver quality
substantia nigra pars compacta	UBERON:0001965	85.84	gold quality
substantia nigra pars reticulata	UBERON:0001966	85.65	silver quality
subthalamic nucleus	UBERON:0001906	85.34	silver quality
cardia of stomach	UBERON:0001162	85.12	silver quality
granulocyte	CL:0000094	85.02	gold quality
dorsal plus ventral thalamus	UBERON:0001897	84.90	silver quality
cerebellar vermis	UBERON:0004720	84.71	gold quality
ventral tegmental area	UBERON:0002691	84.69	silver quality
vastus lateralis	UBERON:0001379	84.59	silver quality
left ovary	UBERON:0002119	84.14	gold quality
stromal cell of endometrium	CL:0002255	83.19	gold quality
pancreatic ductal cell	CL:0002079	83.18	silver quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	83.02	silver quality
pons	UBERON:0000988	82.90	gold quality
body of tongue	UBERON:0011876	82.90	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

176 targeting MDGA1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4728-5P	99.85	69.39	4718

Literature-anchored findings (GeneRIF, showing 5)

• A novel human gene mapped to chromosome 6p21, encodes a putative glycosylphosphatidylinositol (GPI) anchored protein containing a MAM (meprin, A5 antigen, protein tyrosine phosphatase mu) domain. (GPIM) (PMID:12082541)
• MDGA1, a novel glycosylphosphatidylinositol-anchored protein, is localized in lipid rafts. (PMID:15922729)
• MDGA1 is a new schizophrenia susceptibility gene, and altered neuronal migration is involved in SZ pathology. (PMID:18384059)
• The MDGA1 gene may confer risk to schizophrenia and bipolar disorder in Chinese Han population. (PMID:21146959)
• MDGAs regulate the formation of neuroligin-neurexin trans-synaptic bridges by sterically blocking access of neurexins to neuroligins. (PMID:28641112)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mdga1	ENSDARG00000074376
mus_musculus	Mdga1	ENSMUSG00000043557
rattus_norvegicus	Mdga1	ENSRNOG00000000536

Paralogs (4): MDGA2 (ENSG00000139915), MAMDC2 (ENSG00000165072), MAMDC4 (ENSG00000177943), MALRD1 (ENSG00000204740)

Protein

Protein identifiers

MAM domain-containing glycosylphosphatidylinositol anchor protein 1 — Q8NFP4 (reviewed: Q8NFP4)

Alternative names: GPI and MAM protein, Glycosylphosphatidylinositol-MAM, MAM domain-containing protein 3

All UniProt accessions (9): Q8NFP4, A0A3B3IU48, A0A7P0T822, A0A7P0TB21, A0A7P0TB62, D6RFG6, D6RHU8, H0Y4Q2, H0YA23

UniProt curated annotations — full annotation on UniProt →

Function. Required for radial migration of cortical neurons in the superficial layer of the neocortex. Plays a role in the formation or maintenance of inhibitory synapses. May function by inhibiting the activity of NLGN2.

Subunit / interactions. Interacts heterophilically through its MAM domain with proteins in axon-rich regions and through its Ig-like domains with proteins in differentiating muscle. Interacts (through the Ig-like domains) with NLGN2.

Subcellular location. Cell membrane.

Tissue specificity. Has been found in brain, heart, skeletal muscle and kidney. Found to be overexpressed in tumor tissues.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8NFP4-1	1	yes
Q8NFP4-2	2

RefSeq proteins (1): NP_705691* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000998	MAM_dom	Domain
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050958	Cell_Adh-Cytoskel_Orgn	Family

Pfam: PF00629, PF07679, PF13927

UniProt features (65 total): strand 26, glycosylation site 11, domain 8, disulfide bond 6, helix 4, sequence variant 2, signal peptide 1, chain 1, region of interest 1, compositionally biased region 1, lipid moiety-binding region 1, propeptide 1, splice variant 1, turn 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
5V5W	X-RAY DIFFRACTION	2.72
5XEQ	X-RAY DIFFRACTION	3.14
5V5V	X-RAY DIFFRACTION	4.11

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NFP4-F1	84.89	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 932

Disulfide bonds (6): 60–108, 157–214, 262–308, 357–415, 463–514, 560–615

Glycosylation sites (11): 42, 90, 235, 247, 257, 307, 331, 432, 655, 747, 826

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 187 (showing top): GOBP_SPINAL_CORD_DEVELOPMENT, GCACCTT_MIR18A_MIR18B, GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, E2F4DP1_01, GOBP_SYNAPSE_ASSEMBLY, GOCC_CELL_SURFACE, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_CELL_DIFFERENTIATION_IN_SPINAL_CORD, GOBP_FOREBRAIN_DEVELOPMENT, NKX61_01, GOBP_FOREBRAIN_CELL_MIGRATION, GOBP_CELL_CELL_ADHESION, GOBP_STARTLE_RESPONSE

GO Biological Process (13): neuron migration (GO:0001764), nervous system development (GO:0007399), brain development (GO:0007420), spinal cord association neuron differentiation (GO:0021527), cerebral cortex radially oriented cell migration (GO:0021799), dopamine metabolic process (GO:0042417), serotonin metabolic process (GO:0042428), prepulse inhibition (GO:0060134), presynapse assembly (GO:0099054), regulation of synaptic membrane adhesion (GO:0099179), inhibitory synapse assembly (GO:1904862), regulation of presynapse assembly (GO:1905606), cell differentiation (GO:0030154)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (10): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), cell surface (GO:0009986), axon (GO:0030424), dendrite (GO:0030425), side of membrane (GO:0098552), GABA-ergic synapse (GO:0098982), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
synapse assembly	2
membrane	2
neuron projection	2
cell migration	1
generation of neurons	1
system development	1
central nervous system development	1
animal organ development	1
head development	1
cell differentiation in spinal cord	1
dorsal spinal cord development	1
central nervous system neuron differentiation	1
cerebral cortex cell migration	1
catecholamine metabolic process	1
phenol-containing compound metabolic process	1
indole-containing compound metabolic process	1
startle response	1
negative regulation of response to external stimulus	1
cellular component assembly	1
presynapse organization	1
regulation of cell-cell adhesion	1
regulation of synapse organization	1
synaptic membrane adhesion	1
regulation of synapse assembly	1
presynapse assembly	1
regulation of presynapse organization	1
cellular developmental process	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cell periphery	1
dendritic tree	1
leaflet of membrane bilayer	1
synapse	1

Protein interactions and networks

STRING

1520 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MDGA1	NLGN2	Q8NFZ4	848
MDGA1	NTNG2	Q96CW9	594
MDGA1	FN1	P02751	588
MDGA1	NRXN1	Q9ULB1	566
MDGA1	NRXN2	Q9P2S2	562
MDGA1	RORB	Q92753	528
MDGA1	KCNIP2	Q9NS61	491
MDGA1	PTPRM	P28827	480
MDGA1	TMEM19	Q96HH6	456
MDGA1	NTN5	Q8WTR8	441
MDGA1	NLGN3	Q9NZ94	431
MDGA1	DLX1	P56177	429
MDGA1	NLGN1	Q8N2Q7	427
MDGA1	EFNA5	P52803	423
MDGA1	TBR1	Q16650	423

IntAct

3 interactions, top by confidence:

A	B	Type	Score
MDGA1	CDK5	psi-mi:“MI:0915”(physical association)	0.400
SYNGAP1	POTEF	psi-mi:“MI:0914”(association)	0.350

BioGRID (3): NLGN2 (Reconstituted Complex), CDK5 (Affinity Capture-MS), MDGA1 (Two-hybrid)

ESM2 similar proteins: A0A140LHF2, A2AJ76, A6H8M9, A8T688, D3YXG0, E7FF10, O60500, P0C0L4, P0C0L5, P21709, P35590, P43121, P50895, P55144, P55146, P59996, P85171, Q00657, Q05695, Q06805, Q06806, Q0PMG2, Q13308, Q3UH53, Q53RD9, Q60750, Q62786, Q7Z5N4, Q8BKG3, Q8HW98, Q8IZJ3, Q8N0Z9, Q8NBP7, Q8NDA2, Q8NFP4, Q8TDY8, Q923P0, Q96MS0, Q96NU0, Q96RW7

Diamond homologs: A2AJA7, O14786, P28824, P85171, P98072, P98073, P98157, Q0PMG2, Q0WYX8, Q63191, Q6UXC1, Q8NFP4, Q8QFX6, Q9QWJ9, A2AJX4, B3EWZ5, B3EWZ6, B3EX02, C0HL13, O75581, O88572, P35953, P60755, P60756, P97435, P98074, Q2PC93, Q5VYJ5, Q7Z553, Q9GMT4, O35375, P28825, P79795, P97333, Q16820, Q61847, Q64230, A2ARV4, O14522, O60462

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

148 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	128
Likely benign	5
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

3779 predictions. Top by Δscore:

Variant	Effect	Δscore
6:37644495:AC:A	donor_gain	1.0000
6:37644496:CC:C	donor_gain	1.0000
6:37644646:TTGT:T	acceptor_gain	1.0000
6:37644647:TGT:T	acceptor_gain	1.0000
6:37644653:CATTT:C	acceptor_gain	1.0000
6:37644655:T:TC	acceptor_gain	1.0000
6:37644656:T:C	acceptor_gain	1.0000
6:37644656:T:TC	acceptor_gain	1.0000
6:37644657:T:C	acceptor_gain	1.0000
6:37644657:T:TC	acceptor_gain	1.0000
6:37644659:A:AC	acceptor_gain	1.0000
6:37644659:A:C	acceptor_gain	1.0000
6:37644665:C:CT	acceptor_gain	1.0000
6:37646196:A:AC	donor_gain	1.0000
6:37646197:C:CC	donor_gain	1.0000
6:37646197:CG:C	donor_gain	1.0000
6:37646197:CGCT:C	donor_gain	1.0000
6:37646274:G:C	donor_gain	1.0000
6:37646373:CAA:C	acceptor_gain	1.0000
6:37646376:C:CC	acceptor_gain	1.0000
6:37647168:CCCA:C	donor_loss	1.0000
6:37647169:CCA:C	donor_loss	1.0000
6:37647172:C:CT	donor_loss	1.0000
6:37647273:C:CC	acceptor_gain	1.0000
6:37649791:T:TA	donor_gain	1.0000
6:37650107:A:AC	donor_gain	1.0000
6:37650108:C:CC	donor_gain	1.0000
6:37650108:CA:C	donor_gain	1.0000
6:37650108:CACTG:C	donor_gain	1.0000
6:37650426:A:T	acceptor_gain	1.0000

AlphaMissense

6193 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:37638579:C:A	W875C	1.000
6:37638579:C:G	W875C	1.000
6:37638661:A:G	L848P	1.000
6:37643879:A:C	S822R	1.000
6:37643879:A:T	S822R	1.000
6:37643881:T:G	S822R	1.000
6:37644579:C:A	W773C	1.000
6:37644579:C:G	W773C	1.000
6:37644581:A:G	W773R	1.000
6:37644581:A:T	W773R	1.000
6:37647235:A:G	W662R	1.000
6:37647235:A:T	W662R	1.000
6:37650184:A:C	Y512D	1.000
6:37650293:C:A	W475C	1.000
6:37650293:C:G	W475C	1.000
6:37650295:A:G	W475R	1.000
6:37650295:A:T	W475R	1.000
6:37652086:A:C	Y413D	1.000
6:37652210:C:A	W371C	1.000
6:37652210:C:G	W371C	1.000
6:37652212:A:G	W371R	1.000
6:37652212:A:T	W371R	1.000
6:37654433:A:G	W275R	1.000
6:37654433:A:T	W275R	1.000
6:37654870:G:C	C214W	1.000
6:37654872:A:G	C214R	1.000
6:37654916:A:G	L199P	1.000
6:37655772:C:A	W169C	1.000
6:37655772:C:G	W169C	1.000
6:37655773:C:G	W169S	1.000

dbSNP variants (sampled 300 via entrez): RS1000009917 (6:37686639 C>T), RS1000022709 (6:37652774 C>G), RS1000038336 (6:37679748 C>T), RS1000071712 (6:37685537 C>A), RS1000182780 (6:37638445 C>G,T), RS1000189680 (6:37686910 G>C), RS1000198263 (6:37670548 A>G), RS1000207858 (6:37675038 C>G), RS1000265858 (6:37675306 A>G), RS1000280273 (6:37657659 C>G,T), RS1000346277 (6:37697057 G>C,T), RS1000364687 (6:37645539 A>AG), RS1000437087 (6:37657917 C>A,T), RS1000471107 (6:37685580 C>T), RS1000486078 (6:37639841 A>G)

Disease associations

OMIM: gene MIM:609626 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): acute megakaryoblastic leukemia (MONDO:0018872), mediastinal germ cell tumor (MONDO:0021067)

Orphanet (1): Acute megakaryoblastic leukemia (Orphanet:518)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST002481_11	Acne (severe)	2.000000e-06
GCST003560_5	Coronary artery aneurysm in Kawasaki disease	4.000000e-07
GCST005042_8	Restless legs syndrome	3.000000e-26
GCST007387_49	Insomnia symptoms (never/rarely vs. sometimes/usually)	8.000000e-07
GCST007388_38	Insomnia symptoms (never/rarely vs. usually)	3.000000e-08
GCST007576_100	Chronotype	2.000000e-09
GCST008478_23	Neurological blood protein biomarker levels	6.000000e-19
GCST008478_24	Neurological blood protein biomarker levels	7.000000e-91
GCST008478_25	Neurological blood protein biomarker levels	9.000000e-14
GCST008478_26	Neurological blood protein biomarker levels	3.000000e-12
GCST008478_27	Neurological blood protein biomarker levels	5.000000e-11
GCST008478_50	Neurological blood protein biomarker levels	1.000000e-11
GCST008478_62	Neurological blood protein biomarker levels	1.000000e-69
GCST010133_10	Lamb consumption	2.000000e-08
GCST011494_28	Daytime nap	1.000000e-18

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007876	insomnia measurement
EFO:0008328	chronotype measurement
EFO:0008111	diet measurement
EFO:0007828	daytime rest measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007947	Leukemia, Megakaryoblastic, Acute	C04.557.337.539.275.450; C15.378.508.539.275.450

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, decreases methylation, increases expression	2
sodium arsenite	decreases expression, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation	2
Valproic Acid	affects cotreatment, increases expression	2
Aflatoxin B1	decreases methylation	2
aristolochic acid I	increases expression	1
afuresertib	increases expression	1
Esketamine	increases expression	1
sotorasib	increases expression, affects cotreatment	1
beta-lapachone	increases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
butyraldehyde	decreases expression	1
aflatoxin B2	decreases methylation	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	increases expression, affects cotreatment	1
licochalcone B	increases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
Dasatinib	increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	increases expression	1
Estradiol	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

4 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04083170	PHASE2	TERMINATED	Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
NCT00392353	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
NCT01823198	PHASE1/PHASE2	COMPLETED	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
NCT02530619	Not specified	UNKNOWN	Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia